GU Yifeng,WANG Yichao,QI Ao,et al.Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(6):16-19.
GU Yifeng,WANG Yichao,QI Ao,et al.Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(6):16-19. DOI: 10.16305/j.1007-1334.2023.2211037.
Staged rehabilitation treatment strategy of traditional Chinese medicine after non⁃small cell lung cancer surgery
Surgery is the primary approach to eradicate early-stage non-small cell lung cancer(NSCLC). However, postoperative patients are prone to postoperative complications, lung function decline and other issues, which affect the prognosis and quality of life of patients. Therefore, postoperative rehabilitation of NSCLC is gradually being emphasized. In this paper, we put forward that postoperative rehabilitation of NSCLC can be divided into three stages: rapid rehabilitation, consolidation rehabilitation and rehabilitation for recurrence prevention according to the characteristics of each stage. In the stage of rapid rehabilitation, the pathogenesis encompasses phlegm-fluid retained in the lung, qi stagnation in the middle energizer, and stasis obstructing meridians and collaterals. The treatment should be resolving phlegm and expelling fluid retention, unblocking bowel movement and restoring transformation of the spleen, and removing obstruction in collaterals to relieve pain. In the stage of consolidation rehabilitation, the pathogenesis focuses on liver-lung dysregulation and toxicity due to treatment. The treatment should be regulating qi circulation and reducing toxicity and correcting deviation. In the stage of rehabilitation for recurrence prevention, the pathogenesis centers on stagnation of liver-qi and yin deficiency and yang hyperactivity. The treatment should be dispersing stagnated liver qi for relieving qi stagnation, and nourishing yin for suppressing hyperactive yang.
关键词
非小细胞肺癌术后康复化学疗法放射治疗靶向治疗中医药疗法
Keywords
non-small cell lung cancerpostoperative rehabilitationchemotherapyradiotherapytargeted therapytraditional Chinese medicine therapy
ALLEN M S, DARLING G E, PECHET T T, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial[J]. Ann Thorac Surg, 2006, 81(3): 1013-1020.
BOFFA D J, ALLEN M S, GRAB J D, et al. Data from the society of thoracic surgeons general thoracic surgery database: the surgical management of primary lung tumors[J]. J Thorac Cardiovasc Surg, 2008, 135(2): 247-254.
RUETH N M, ANDRADE R S. Is VATS lobectomy better: perioperatively, biologically and oncologically?[J]. Ann Thorac Surg, 2010, 89(6): S2107-S2111.
RUETH N M, PARSONS H M, HABERMANN E B, et al. The long-term impact of surgical complications after resection of stage I nonsmall cell lung cancer: a population-based survival analysis[J]. Ann Surg, 2011, 254(2): 368-374.
WIN T, SHARPLES L, WELLS F C, et al. Effect of lung cancer surgery on quality of life[J]. Thorax, 2005, 60(3): 234-238.
JrHANDY J R, ASAPH J W, SKOKAN L, et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery[J]. Chest, 2002, 122(1): 21-30.
JIAO L, XU J, SUN J, et al. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): a multicenter, randomized, double-blind, placebo-controlled trial[J]. Front Pharmacol, 2019, 10: 732.
WANG Q, JIAO L, WANG S, et al. Maintenance chemotherapy with Chinese herb medicine formulas vs. with placebo in patients with advanced non-small cell lung cancer after first-line chemotherapy: a multicenter, randomized, double-blind trial[J]. Front Pharmacol, 2018, 9: 1233.
Based on theory of “all cold with contraction belong to the kidney” to explore the treatment of myelosuppression after chemotherapy for gastric cancer from kidney
Propensity score matching analysis of the effect of the Yiqi Yangjing Prescription on the survival prognosis of patients with stage Ⅰ⁃ⅢA lung adenocarcinoma after surgery
Effect of Buyi Xiaozheng Prescription on immune microenvironment in window period of chemotherapy for advanced ovarian cancer
Efficacy and safety of Yiqi Yangyin Jiedu regimen plus anlotinib in the treatment of advanced non⁃small cell lung cancer
Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer
Related Author
No data
Related Institution
Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Department of Integrative Medicine, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Department of Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Renji Hospital, Shanghai Jiaotong University School of Medicine
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine